Familial cutaneous melanoma

Advances in Experimental Medicine and Biology

Volumn 685, Issue , 2010, Pages 134-145

  Hansson, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; CANCER RISK; CDK4 GENE; CDKN2A GENE; CELL CYCLE PROGRESSION; CHROMOSOME 12Q; CHROMOSOME 12Q14; CHROMOSOME 9P; CHROMOSOME 9P21; DISEASE PREDISPOSITION; ENZYME REGULATION; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FAMILIAL CUTANEOUS MELANOMA; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC SCREENING; HEREDITY; HUMAN; INCIDENCE; MELANOMA; MOLECULAR GENETICS; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN INTERACTION; SENESCENCE; SKIN CANCER; ANIMAL; CHROMOSOME 12; FAMILY; FEMALE; GENETIC DISORDER; GENETICS; MALE; METABOLISM; MUTATION; PANCREAS TUMOR; PATHOLOGY; PEDIGREE; REVIEW; RISK FACTOR; SKIN TUMOR;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 12; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FAMILY; FEMALE; GENETIC DISEASES, INBORN; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; PANCREATIC NEOPLASMS; PEDIGREE; RISK FACTORS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 77955878053     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6448-9_13     Document Type: Article

References (83)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 7. CA Cancer J Clin 2007; 57:43-66.
2. Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41:45-60. (Pubitemid 40029658)
3. Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41:28-44. (Pubitemid 40029657)
4. Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41:2040-2059. (Pubitemid 41337946)
5. Platz A, Ringborg U, Hansson J. Hereditary cutaneous melanoma. Semin Cancer Biol 2000; 10:319-326.
6. Florell SR, Boucher KM, Garibotti G et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 2005; 23:7168-7177.
7. Ford D, Bliss JM, Swerdlow AJ et al. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995; 62:377-381.
8. Greene MH, Clark WH Jr, Tucker MA et al. Precursor naevi in cutaneous malignant melanoma: A proposed nomenclature. Lancet 1980; 2:1024. (Pubitemid 10025088)
9. Begg CB, Hummer A, Mujumdar U et al. Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes Control 2004; 15:957-965. (Pubitemid 39663872)
10. Norris W. Case of fungoid disease. Edinburgh Med Surg J 1820; 16:562-565.
11. Clark WH Jr, Reimer RR, Greene M et al. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978; 114:732-738.
12. Lynch HT, Frichot BC 3rd, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978; 15:352-356. (Pubitemid 9041252)
13. Newton Bishop JA, Bataille V, Pinney E et al. Family studies in melanoma: Identification of the atypical mole syndrome (AMS) phenotype. Melanoma Res 1994; 4(4):199-206. (Pubitemid 24257666)
14. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: The role of physician examination and self-examination of the skin. CA Cancer J Clin 1985; 35(3):130-151. (Pubitemid 15041543)
15. Hofmann-Wellenhof R, Blum A, Wolf IH et al. Dermoscopic classification of Clark's nevi (atypical melanocytic nevi). Clin Dermatol 2002; 20(3):255-258. (Pubitemid 34628892)
16. Roesch A, Burgdorf W, Stolz W et al. Dermatoscopy of "dysplastic nevi": A beacon in diagnostic darkness. Eur J Dermatol 2006; 16(5):479-493. (Pubitemid 44861821)
17. Goldstein AM, Fraser MC, Clark WH Jr et al. Age at diagnosis and transmission of invasive melanoma in 23 families with cutaneous malignant melanoma/dysplastic nevi. J Natl Cancer Inst 1994; 86(18):1385-1390. (Pubitemid 24283357)
18. Greene MH, Clark WH Jr, Tucker MA et al. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985; 102(4):458-465. (Pubitemid 15109001)
19. Marks R, Dorevitch AP, Mason G. Do all melanomas come from "moles"? A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol 1990; 31(2):77-80.
20. Carey WP Jr, Thompson CJ, Synnestvedt M et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 1994; 74(12):3118-3125. (Pubitemid 24375068)
21. Hussussian CJ, Struewing JP, Goldstein AM et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8(1):15-21. (Pubitemid 24274055)
22. Kamb A, Gruis NA, Weaver-Feldhaus J et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264(5157):436-440.
23. de Snoo FA, Hayward NK. Cutaneous melanoma susceptibility and progression genes. Cancer Lett 2005; 230(2):153-186. (Pubitemid 41613885)
24. Platz A, Egyhazi S, Ringborg U et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008; 1(4):395-405.
25. Pollock PM, Harper UL, Hansen KS et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33(1):19-20. (Pubitemid 36068675)
26. Michaloglou C, Vredeveld LC, Soengas MS et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436(7051):720-724. (Pubitemid 41117276)
27. Gray-Schopfer VC, Cheong SC, Chong H et al. Cellular senescence in naevi and immortalisation in melanoma: A role for p16? Br J Cancer 2006; 95(4):496-505. (Pubitemid 44232559)
28. Florell SR, Meyer LJ, Boucher KM et al. Longitudinal assessment of the nevus phenotype in a melanoma kindred. J Invest Dermatol 2004; 123(3):576-582. (Pubitemid 39095630)
29. Sviderskaya EV, Gray-Schopfer VC, Hill SP et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis and immortalization: Possible implications for melanoma progression. J Natl Cancer Inst 2003; 95(10):723-732. (Pubitemid 36665500)
30. Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS 2007; 115(10):1161-1176. (Pubitemid 350179478)
31. Bennett DC. How to make a melanoma: What do we know of the primary clonal events? Pigment Cell Melanoma Res 2008; 21(1):27-38. (Pubitemid 351421467)
32. Rizos H, Woodruff S, Kefford RF. p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. Cell Cycle 2005; 4(4):597-603. (Pubitemid 41359789)
33. Rizos H, Scurr LL, Irvine M et al. p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism. Cell Cycle 2007; 6(14):1741-1747. (Pubitemid 47327927)
34. Monzon J, Liu L, Brill H et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998; 338(13):879-887. (Pubitemid 28135965)
35. MacKie RM, Andrew N, Lanyon WG et al. CDKN2A germline mutations in UK patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 1998; 111(2):269-272. (Pubitemid 28354714)
36. Hashemi J, Platz A, Ueno T et al. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 2000; 60(24):6864-6867. (Pubitemid 32059154)
37. Auroy S, Avril MF, Chompret A et al. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 2001; 32(3):195-202. (Pubitemid 32953973)
38. Bahuau M, Vidaud D, Jenkins RB et al. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 1998; 58(11):2298-2303. (Pubitemid 28252682)
39. Hewitt C, Lee Wu C, Evans G et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 2002; 11(11):1273-1279. (Pubitemid 34555524)
40. Petronzelli F, Sollima D, Coppola G et al. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf ) RNA processing in a melanoma/neurofibroma kindred. Genes Chromosomes Cancer 2001; 31(4):398-401. (Pubitemid 32622717)
41. Randerson-Moor JA, Harland M, Williams S et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001; 10(1):55-62. (Pubitemid 32051568)
42. Rizos H, Puig S, Badenas C et al. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 2001; 20(39):5543-5547. (Pubitemid 32889492)
43. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003; 22(20):3053-3062. (Pubitemid 36713755)
44. Goldstein AM, Chan M, Harland M et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors and uveal melanoma across GenoMEL. Cancer Res 2006; 66(20):9818-9828. (Pubitemid 44672032)
45. Platz A, Hansson J, Mansson-Brahme E et al. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997; 89(10):697-702. (Pubitemid 27229857)
46. Gruis NA, Sandkuijl LA, van der Velden PA et al. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 1995; 5(3):169-177.
47. Goldstein AM, Stacey SN, Olafsson JH et al. CDKN2A Mutations and Melanoma Risk in the Icelandic Population. J Med Genet 2008.
48. Ciotti P, Struewing JP, Mantelli M et al. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet 2000; 67(2):311-319. (Pubitemid 30616738)
49. Zuo L, Weger J, Yang Q et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12(1):97-99. (Pubitemid 26013159)
50. Soufir N, Avril MF, Chompret A et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998; 7(2):209-216. (Pubitemid 28048536)
51. Molven A, Grimstvedt MB, Steine SJ et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi and CDK4 mutation. Genes Chromosomes Cancer 2005; 44(1):10-18. (Pubitemid 41060192)
52. Pjanova D, Molven A, Akslen LA et al. Identification of a CDK4 R24H mutation-positive melanoma family by analysis of early-onset melanoma patients in Latvia. Melanoma Res 2009; 19(2):119-122.
53. Gillanders E, Juo SH, Holland EA et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003; 73(2):301-313. (Pubitemid 36920993)
54. Walker GJ, Indsto JO, Sood R et al. Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval. Genes Chromosomes Cancer 2004; 41(1):56-64. (Pubitemid 38988738)
55. Jonsson G, Bendahl PO, Sandberg T et al. Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32. J Natl Cancer Inst 2005; 97(18):1377-1382. (Pubitemid 41487805)
56. Begg CB, Orlow I, Hummer AJ et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005; 97(20):1507-1515. (Pubitemid 41631950)
57. Goldstein AM, Fraser MC, Struewing JP et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333(15):970-974.
58. Borg A, Sandberg T, Nilsson K et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92(15):1260-1266. (Pubitemid 30627734)
59. Goldstein AM. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 2004; 23(6):630.
60. de Snoo FA, Bishop DT, Bergman W et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 2008; 14(21):7151-7157.
61. Hille ET, van Duijn E, Gruis NA et al. Excess cancer mortality in six Dutch pedigrees with the familial atypical multiple mole-melanoma syndrome from 1830 to 1994. J Invest Dermatol 1998; 110(5):788-792. (Pubitemid 28194029)
62. Newton Bishop JA, Gruis NA. Genetics: What advice for patients who present with a family history of melanoma? Semin Oncol 2007; 34(6):452-459. (Pubitemid 350236306)
63. Botkin JR, Smith KR, Croyle RT et al. Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 2003; 118(3):201-209. (Pubitemid 37063927)
64. Hadley DW, Jenkins JF, Dimond E et al. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 2004; 22(1):39-44. (Pubitemid 41095112)
65. Leachman SA, Carucci J, Kohlmann W et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009; 61(4):677 e671-614.
66. Kefford RF, Newton Bishop JA, Bergman W et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999; 17(10):3245-3251. (Pubitemid 29470659)
67. Bishop DT, Demenais F, Goldstein AM et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002; 94(12):894-903. (Pubitemid 34778088)
68. National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, 1992. Am J Dermatopathol 1993; 15(1):34-43; discussion 46-51.
69. Ferrini RL, Perlman M, Hill L. American College of Preventive Medicine practice policy statement: Skin protection from ultraviolet light exposure. The American College of Preventive Medicine. Am J Prev Med 1998; 14(1):83-86. (Pubitemid 28099240)
70. Krien PM, Moyal D. Sunscreens with broad-spectrum absorption decrease the trans to cis photoisomerization of urocanic acid in the human stratum corneum after multiple UV light exposures. Photochem Photobiol 1994; 60(3):280-287.
71. Kenet RO, Kang S, Kenet BJ et al. Clinical diagnosis of pigmented lesions using digital epiluminescence microscopy. Grading protocol and atlas. Arch Dermatol 1993; 129(2):157-174. (Pubitemid 23063868)
72. Menzies SW, Ingvar C, McCarthy WH. A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma. Melanoma Res 1996; 6(1):55-62. (Pubitemid 26066855)
73. Kelly JW, Yeatman JM, Regalia C et al. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust 1997; 167(4):191-194. (Pubitemid 27387245)
74. McGovern TW, Litaker MS. Clinical predictors of malignant pigmented lesions. A comparison of the Glasgow seven-point checklist and the American Cancer Society's ABCDs of pigmented lesions. J Dermatol Surg Oncol 1992; 18(1):22-26.
75. Shaw HM, McCarthy WH. Small-diameter malignant melanoma: A common diagnosis in New South Wales, Australia. J Am Acad Dermatol 1992; 27(5 Pt 1):679-682.
76. Rhodes AR. Intervention strategy to prevent lethal cutaneous melanoma: Use of dermatologic photography to aid surveillance of high-risk persons. J Am Acad Dermatol 1998; 39(2 Pt 1):262-267. (Pubitemid 28367339)
77. Masri GD, Clark WH Jr, Guerry Dt et al. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 1990; 22(6 Pt 1):1042-1048. (Pubitemid 20186126)
78. MacKie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet 1993; 341(8861):1618-1620. (Pubitemid 23175245)
79. Tucker MA, Fraser MC, Goldstein AM et al. A natural history of melanomas and dysplastic nevi: An atlas of lesions in melanoma-prone families. Cancer 2002; 94(12):3192-3209. (Pubitemid 34670503)
80. Hansson J, Bergenmar M, Hofer PA et al. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: Results of a Swedish preventive program. J Clin Oncol 2007; 25(19):2819-2824. (Pubitemid 47123192)
81. Parker JF, Florell SR, Alexander A et al. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol 2003; 139(8):1019-1025. (Pubitemid 36994827)
82. Brand RE, Lerch MM, Rubinstein WS et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007; 56(10):1460-1469. (Pubitemid 47517845)
83. Lynch HT, Fusaro RM, Lynch JF et al. Pancreatic cancer and the FAMMM syndrome. Fam Cancer 2008; 7(1):103-112.